
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - A study demonstrating the importance of the development and functions of the stratum corneum acid mantle in adult murine and neonatal rat models may have important implications for developing therapies for humans.